Lipoprotein(a), often written as Lp(a) and pronounced “L-P-little-a,” is a cholesterol-carrying particle whose blood levels are almost entirely set by your genes rather than your lifestyle. Unlike regular LDL cholesterol, Lp(a) barely budges with diet, exercise, or most cholesterol-lowering drugs, which is why it catches many people off guard when it shows up elevated on a blood test. High Lp(a) is an independent risk factor for heart attack, stroke, aortic valve disease, and peripheral artery disease, and roughly one in five people worldwide carries levels considered elevated. What makes Lp(a) both frustrating and increasingly important is that the medical toolkit for treating it directly has been limited for decades, though a new wave of targeted drugs is now in late-stage trials.
What Lp(a) Actually Is
Lp(a) looks a lot like ordinary LDL cholesterol under a microscope. It has the same core of cholesterol, the same outer shell of phospholipids, and the same apolipoprotein B100 protein on its surface. The key difference is an extra protein called apolipoprotein(a), or apo(a), that latches onto apo B100 through a chemical bond called a disulfide bridge.1PubMed Central. Lipoprotein (a): structure, pathophysiology and clinical implications That extra protein changes how the particle behaves in the bloodstream. Research shows that the attachment of apo(a) actually alters the structure of apo B itself, modifying how the particle interacts with cells and receptors.2PubMed. The linkage with apolipoprotein (a) in lipoprotein (a) modifies the immunochemical and functional properties of apolipoprotein B
Apo(a) has a structure strikingly similar to plasminogen, a protein your body uses to dissolve blood clots. That resemblance is not a coincidence, and it lies at the heart of why Lp(a) is so harmful. Because apo(a) mimics plasminogen, Lp(a) can bind to the same spots on blood vessel walls and on fibrin (the scaffolding of clots), effectively elbowing plasminogen out of the way and slowing down the body’s natural clot-dissolving system.3Brazilian Journal of Medical and Biological Research. Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process So Lp(a) delivers cholesterol into artery walls like LDL, but it also hampers clot cleanup, a double threat.
Why Lp(a) Levels Are Almost Entirely Genetic
If you have high Lp(a), there is very little you did to cause it and very little you can do through behavior change to fix it. Blood levels are largely determined by variations in the LPA gene, which encodes the apo(a) protein. One of the biggest genetic drivers is the number of repeating structural units within the gene, known as Kringle IV type 2 (KIV-2) copies. Fewer copies of this segment lead to a smaller apo(a) protein and, paradoxically, higher Lp(a) concentrations, while more copies lead to a larger protein and lower levels.4Journal of the American Heart Association. LPA Kringle IV Type-2 Genetic Variants Are Associated With Apolipoprotein (a) Size, Hypertension, and Nonfasting Glucose Levels
Cross-sectional and intervention studies consistently show that standard lipid-lowering strategies, including low-fat diets, weight loss, and moderate exercise, have little meaningful effect on Lp(a).5PubMed. Effects of physical activity and diet on lipoprotein(a) That finding has held up across multiple types of studies. Lp(a) stays relatively constant within a given individual over time and does not respond to the lifestyle changes that reliably move LDL, HDL, and triglycerides.6PubMed. Effects of exercise on lipoprotein(a) This genetic stubbornness is what separates Lp(a) from most other cardiovascular risk factors and is why it requires its own management strategy.
How High Lp(a) Damages Blood Vessels
Lp(a) promotes atherosclerosis through several overlapping pathways. It damages the endothelium (the thin inner lining of arteries), triggers inflammation, and encourages cholesterol to accumulate and oxidize inside artery walls. These changes drive the formation of foam cells and activate smooth muscle cells, both early hallmarks of plaque buildup.7PubMed Central. Presumed Mechanisms Underlying Lipoprotein(a)-caused Atherosclerosis Animal studies have confirmed that Lp(a) breaks down faster inside existing plaques than in healthy tissue, suggesting it actively feeds plaque growth once the process starts.8PubMed. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits
A major reason Lp(a) packs such an outsized punch relative to its concentration in the blood comes down to a specific cargo it carries: oxidized phospholipids, or OxPL. Lp(a) is the main carrier of these inflammatory molecules in human plasma. The OxPL on Lp(a) activate monocytes (a type of white blood cell), damage endothelial cells, stimulate smooth muscle cells, and even harm the cells inside heart valves.9PubMed. Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology In lab experiments, when researchers inactivated or removed the OxPL from Lp(a), the inflammatory response in human monocytes dropped substantially.10PubMed Central. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans This explains a puzzle that has long intrigued researchers: Lp(a) circulates at concentrations roughly ten times lower than LDL, yet it contributes powerfully to cardiovascular risk. The OxPL payload is what makes the difference.
On top of all that, because apo(a) mimics plasminogen, elevated Lp(a) effectively tilts the balance toward clot formation. By binding to fibrin and to receptors on endothelial cells and monocytes, Lp(a) inhibits the generation of plasmin, the enzyme that dissolves clots. The result is that cholesterol and fibrin build up faster at sites of vascular injury.3Brazilian Journal of Medical and Biological Research. Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process
Cardiovascular Risks Linked to High Lp(a)
Elevated Lp(a) is an independent risk factor for several forms of cardiovascular disease. The strongest evidence supports connections to ischemic heart disease, aortic valve stenosis, and heart failure.11PubMed Central. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives “Independent” is the key word here: Lp(a) increases your risk even after accounting for your LDL, blood pressure, smoking status, and other traditional factors.
The link to aortic valve stenosis deserves special attention because it is both well-established and still underappreciated. A meta-analysis of five studies found that people in the highest Lp(a) group had about 40% faster progression of aortic valve narrowing (measured by jet velocity) and roughly 60% faster progression of the pressure gradient across the valve compared with those in the lowest group.12JAMA Cardiology. Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis A separate study of patients already diagnosed with calcific aortic valve stenosis found that those with Lp(a) at or above 125 nmol/L had about a 60% higher rate of needing valve replacement compared with those below that threshold.13PubMed Central. Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve Stenosis
Peripheral artery disease and abdominal aortic aneurysm are also tied to Lp(a), though the evidence has been considered less conclusive than for coronary disease. A large study found a clear stepwise increase in risk: people with Lp(a) at or above the 99th percentile had roughly triple the risk of peripheral artery disease and about double the risk of abdominal aortic aneurysm compared to those below the 50th percentile.14PubMed. Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events
Who Tends to Have Higher Levels
Lp(a) levels vary substantially across racial and ethnic groups, driven by differences in LPA gene variants rather than by diet or socioeconomic factors. Among the groups studied, Black individuals have the highest average Lp(a) levels, followed by South Asians, then White individuals, Hispanics, and East Asians.15PubMed. Lipoprotein(a) and ethnicities A U.S. study looking at disaggregated subgroups found that over 60% of non-Hispanic Black individuals had Lp(a) at or above 50 mg/dL, compared with about 30% of Mexican-American individuals. After adjusting for other factors, Black individuals had roughly 2.5 times the odds of elevated Lp(a) compared with the reference group, while Hispanic and Asian individuals had lower odds.16PubMed Central. Lipoprotein(a) Levels in Disaggregated Racial and Ethnic Subgroups Across Atherosclerotic Cardiovascular Disease Risk Levels
These population-level differences matter for clinical awareness. A physician who rarely tests Lp(a) may be missing a major contributor to cardiovascular risk, especially in patients of African or South Asian descent who have heart disease that seems disproportionate to their standard lipid panel. And because Lp(a) levels are set genetically, the disparity is not something that public-health messaging around diet and exercise can close.
Testing Challenges and Why Units Matter
One of the frustrating wrinkles of Lp(a) testing is that the numbers on your lab report may not mean what you think they mean. Lp(a) can be reported in mass units (mg/dL) or molar units (nmol/L), and there is no reliable way to convert between the two. The conversion factor varies depending on the assay used, the threshold chosen, and even the size of the apo(a) protein in the individual being tested.17PubMed. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size A single fixed conversion factor, which some labs and online calculators still use, is not appropriate.
The reason the conversion is unreliable relates to the unique structure of apo(a). Because antibodies used in assays tend to bind to the repeating KIV-2 units, and the number of those units varies from person to person, measuring the total mass of Lp(a) captures different amounts of apo(a) protein depending on the individual’s isoform size.18Atherosclerosis. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? The field is moving toward reporting in nmol/L because molar concentrations count the number of Lp(a) particles regardless of size, which more accurately reflects risk. If your lab report shows only mg/dL, do not try to convert it yourself. Instead, ask your doctor whether the lab used an isoform-insensitive assay.
Common risk thresholds cited in guidelines are around 50 mg/dL or 125 nmol/L, but these should be understood as approximate cut-points for elevated risk, not precise triggers. Growing expert consensus favors testing all adults at least once in their lifetime, since Lp(a) levels remain stable and a single measurement generally tells you what you need to know.19PubMed Central. Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees
Why Statins Do Not Lower Lp(a)
Many people with high Lp(a) are already on statins for their LDL cholesterol, and it is natural to assume those drugs would help with Lp(a) too. They don’t. A meta-analysis of 43 studies found that the average change in Lp(a) concentration on statin therapy was 0.22 mg/dL, a meaningless amount clinically.20PubMed Central. Statins—Their Effect on Lipoprotein(a) Levels A separate systematic review reached the same conclusion: no type or intensity of statin therapy produced a significant change in Lp(a) compared with placebo.21European Journal of Preventive Cardiology. Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis
This does not mean statins are useless for someone with elevated Lp(a). They still lower LDL, and an older but instructive study found that aggressively lowering LDL could blunt the harm of high Lp(a). Among patients whose Lp(a) was at or above the 90th percentile, cardiovascular events occurred in about 39% of those with minimal LDL reduction but only about 9% of those with substantial LDL reduction.22JAMA. Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a) In other words, while you may not be able to lower Lp(a) directly, getting your LDL as low as possible makes the Lp(a) you do have less dangerous. This remains a core part of management strategy for most patients.
Currently Available Treatments That Do Lower Lp(a)
Today, the only approved therapies that meaningfully lower Lp(a) and have shown cardiovascular benefit are PCSK9 inhibitors and lipoprotein apheresis.23Atherosclerosis. Existing and emerging strategies to lower Lipoprotein(a) PCSK9 inhibitors, such as evolocumab, are injectable drugs primarily prescribed for very high LDL. They also reduce Lp(a) as a secondary effect. In one large trial, evolocumab lowered Lp(a) by a median of roughly 27% at 48 weeks, with considerable variation between individuals.24PubMed. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk That reduction is helpful but modest, especially for people whose levels start very high.
Lipoprotein apheresis is a more aggressive option. It works like dialysis for lipids: blood is drawn, run through a machine that physically removes Lp(a) and LDL particles, and returned to the body. Sessions typically happen every one to two weeks. Clinical studies show apheresis can reduce Lp(a) by 60 to 80%, and sustained treatment over two to five years has been associated with proportional decreases in cardiovascular events and even regression of atherosclerotic plaques.25PubMed. Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia The downsides are significant: it is time-consuming, expensive, available only at specialized centers, and the effect wears off between sessions, so levels bounce back partially within days.
RNA-Based Drugs on the Horizon
The most exciting development in Lp(a) management is a new class of drugs that use RNA technology to silence the LPA gene, stopping the liver from producing apo(a) in the first place. Several candidates are in clinical trials, including pelacarsen, olpasiran, lepodisiran, and zerlasiran.26PubMed Central. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?
The reductions these drugs achieve are dramatic compared with anything previously available. In a phase 2 trial, olpasiran lowered Lp(a) by about 70% at the lowest dose tested, and by over 95% at higher doses, with effects sustained for months after a single injection.27PubMed. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease Olpasiran works by using small interfering RNA to block the gene encoding apo(a), preventing the protein from being made.28PubMed. Advances in RNA-Based Therapies Targeted at Lipoprotein(a): Olpasiran in the Management of Atherosclerotic Cardiovascular Disease
What remains to be proven is whether these massive reductions in Lp(a) actually translate into fewer heart attacks, strokes, and deaths. Several large phase 3 outcome trials are underway and expected to report in the coming years. Until those results are in, none of these drugs are available outside of clinical trials. But the field is cautiously optimistic because of how strong the genetic evidence is that high Lp(a) causes cardiovascular disease, not merely accompanies it.
Screening Your Family
Because Lp(a) is so strongly inherited, finding one person with elevated levels means their close relatives have a high probability of being affected too. Cascade screening, where you systematically test the first-degree relatives of someone with high Lp(a), is remarkably efficient. One study found that about two out of every three relatives tested had Lp(a) at or above 50 mg/dL, and the detection rate climbed to over 80% when the index case had levels above 150 mg/dL.29American Journal of Preventive Cardiology. Cascade testing for elevated lipoprotein(a) in relatives of probands with high lipoprotein(a) In practical terms, cascade screening identifies roughly one new case of elevated Lp(a) for every 1.5 to 2.9 relatives screened, depending on the threshold used.30PubMed Central. Effectiveness of cascade screening for elevated lipoprotein(a), an underdiagnosed family disorder
The case for screening extends to children. In families with both familial hypercholesterolemia and elevated Lp(a), cascade testing identified one child or adolescent with elevated Lp(a) for every two tested, compared with one for every 7.5 tested in families where the index case had normal Lp(a).31PubMed. Cascade testing of children and adolescents for elevated Lp(a) in pedigrees with familial hypercholesterolaemia Early identification matters because it changes how aggressively physicians manage other risk factors like LDL, blood pressure, and smoking over a patient’s lifetime. Even without a targeted Lp(a) drug, knowing that you or your child carries elevated Lp(a) reshapes the risk calculation for everything else.
Hormonal Influences on Lp(a)
One area where Lp(a) levels do appear to shift is around hormonal changes, particularly in women. In the Heart and Estrogen/progestin Replacement Study, postmenopausal women randomized to hormone therapy experienced a significant average reduction in Lp(a) of about 5.8 mg/dL over one year, while those on placebo saw essentially no change. The reduction was greatest in women who had the highest Lp(a) levels to begin with.32JAMA. Estrogen and Progestin, Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause Data from the Framingham Offspring Study noted that postmenopausal women tended to have somewhat higher Lp(a) than premenopausal women, though the difference was modest and not statistically significant after adjusting for age.33PubMed. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study
These findings have not led to recommendations to use hormone therapy specifically for Lp(a) reduction, because the overall risk-benefit profile of hormone replacement is governed by many other factors. But they do suggest that women transitioning through menopause who already know they have high Lp(a) should pay particular attention to cardiovascular risk management during that period.
Why Lp(a) Exists at All
Given how harmful Lp(a) clearly is to cardiovascular health, it is fair to wonder why evolution did not wipe it out. The protein is found only in humans, Old World primates, and oddly enough the European hedgehog, suggesting it arose independently in these lineages and may serve a purpose that outweighed its harms in ancestral environments.34PubMed. Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels The leading theory is that Lp(a) played a role in wound healing. By binding to platelets and macrophages and promoting fibrin formation at injury sites, Lp(a) may have helped seal wounds and deliver cholesterol for tissue repair at a time when trauma and infection, not atherosclerosis, were the primary killers.35PubMed. Lipoprotein (a) In a world where humans rarely lived long enough for plaque to build up, the clot-promoting properties of Lp(a) were a survival advantage. In the modern world, where people live decades longer and eat diets that promote chronic vascular inflammation, those same properties become a liability.